TY - JOUR T1 - Serum but not mucosal antibody responses are predicted by pre-existing SARS-CoV-2 spike cross-reactive CD4<sup>+</sup> T cells following BNT162b2 vaccination in the elderly JF - medRxiv DO - 10.1101/2021.10.05.21264545 SP - 2021.10.05.21264545 AU - Lil Meyer-Arndt AU - Tatjana Schwarz AU - Lucie Loyal AU - Larissa Henze AU - Beate Kruse AU - Manuela Dingeldey AU - Kübrah Gürcan AU - Zehra Uyar-Aydin AU - Marcel A. Müller AU - Christian Drosten AU - Friedemann Paul AU - Leif E. Sander AU - Ilja Demuth AU - Roland Lauster AU - Claudia Giesecke-Thiel AU - Julian Braun AU - Victor M. Corman AU - Andreas Thiel Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264545.abstract N2 - Advanced age is a main risk factor for severe COVID-19 and thus elderly were often prioritized for vaccination. However, low vaccination efficacy and accelerated waning immunity have been reported in this age group. To elucidate age-related differences in immunogenicity, we analysed cellular, serological and salivary SARS-CoV-2 spike glycoprotein-specific immune responses to BNT162b2 COVID-19 vaccine in old (69-92 years) and middle-aged (24-57 years) vaccinees compared to natural infection (COVID-19 convalescents of 21-55 years). Serological humoral responses to vaccination exceeded those of convalescents but salivary anti-spike subunit 1 (S1) IgA and neutralizing capacity were less durable in vaccinees. In old vaccinees, we observed that pre-existing spike-specific CD4+ T cells correlated with efficient induction of serological anti-S1 IgG and neutralizing capacity after vaccination. Our results highlight the role of pre-existing cross-reactive CD4+ T cells with respect to SARS-CoV-2 vaccination particularly in old individuals, in whom their presence predicted efficient COVID-19-vaccine-induced humoral immune responses.Competing Interest StatementVMC and MAM are named together with Euroimmun on a patent application filed recently regarding detection of antibodies against SARS-CoV-2.Funding StatementGerman Federal Ministery of Health to AT (Charite Corona Cross (CCC)) and to CD and VMC (Konsiliarlabor fuer Coronaviren). German Ministry of Research through VARIPath (01KI2021) to VMC. German Research Foundation through KFO339 to JB. In part by the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF) to NaFoUniMedCovid19, COVIM, FKZ 01KX2021.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee Charite - Universitaetsmedizin BerlinI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request. ER -